secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001157523-22-001608
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Q3 net loss $43.3M ($0.55/share), cash $343.7M, appoints CEO/CMO
-----------------------------------------------------------------------------

- Net loss of $43.3M ($0.55/share) vs $37.5M loss in Q3 2021; zero revenue vs $5.5M prior year.
- Cash, equivalents, and marketable securities $343.7M as of Sep 30, 2022, expected to fund operations into 2025.
- Appointed Jay Backstrom as President & CEO (Oct) and Jing Marantz as CMO (Nov).
- Amended debt facility with Oxford/SVB adding $25M capacity, extending interest-only period to Nov 2024 and maturity to Nov 2027.
- Phase 3 SAPPHIRE trial for apitegromab enrolling ~156 patients; Phase 1 DRAGON shows confirmed PR in ccRCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000115752322001608/0001157523-22-001608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000115752322001608/a52967670.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer